This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CBLI Cleveland BioLabs (CBLI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Cleveland BioLabs Stock (NASDAQ:CBLI) 30 days 90 days 365 days Advanced Chart Get Cleveland BioLabs alerts:Sign Up Key Stats Today's Range$0.0002▼$0.000250-Day Range$2.20▼$4.3452-Week Range$1.62▼$10.97Volume1,052 shsAverage Volume271,922 shsMarket Capitalization$3.10 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO. Read More Receive CBLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cleveland BioLabs and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CBLI Stock News HeadlinesEagles' Tyrie Cleveland, Moro Ojomo carted off field after suffering neck injuriesSeptember 2, 2023 | usatoday.comCleveland Construction NewsJuly 28, 2023 | bizjournals.comA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.August 28 at 2:00 AM | Investors Alley (Ad)Best Hospitals in Cleveland, OHJune 28, 2023 | health.usnews.comCleveland EMS worker who went missing for 6 days remains hospitalized after found safeMay 22, 2023 | abcnews.go.comCleveland Clinic Rehabilitation HospitalMay 17, 2023 | health.usnews.comGetting Around ClevelandApril 18, 2023 | travel.usnews.comCleveland BioLabs Stock Gaps Down On Today's Open (CBLI)March 31, 2023 | thestreet.comSee More Headlines CBLI Stock Analysis - Frequently Asked Questions How were Cleveland BioLabs' earnings last quarter? Cleveland BioLabs, Inc. (NASDAQ:CBLI) posted its quarterly earnings results on Friday, May, 15th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The biotechnology company earned $0.16 million during the quarter. What other stocks do shareholders of Cleveland BioLabs own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cleveland BioLabs investors own include iBio (IBIO), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Novavax (NVAX) and BioCryst Pharmaceuticals (BCRX). Company Calendar Last Earnings5/15/2020Today8/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CBLI CIK1318641 Webwww.cbiolabs.com Phone(888) 613-8802FaxN/AEmployees4Year Founded2003Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.40 million Net MarginsN/A Pretax MarginN/A Return on Equity-32.84% Return on Assets-31.29% Debt Debt-to-Equity RatioN/A Current Ratio45.93 Quick Ratio45.93 Sales & Book Value Annual Sales$260 thousand Price / Sales0.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book0.00Miscellaneous Outstanding Shares15,479,000Free FloatN/AMarket Cap$3.10 thousand OptionableNot Optionable Beta0.70 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CBLI) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cleveland BioLabs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cleveland BioLabs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access